Pelage presents latest data at AAD 2024 meeting demonstrating that PP405 activates human hair follicle stem cells in vitro and in Phase 1 clinical trials

– Potent topical MPC inhibitor based on metabolic switch discovery reawakenss Dormant hair follicle stem cells to stimulate hair growth

-PP405dDemonstrate statistically significant activation Ki67 within the hair folliclean established marker of stem cell proliferation

Los Angeles, March 9, 2024 /PRNewswire/ — perage pharmaceuticalThe company, a clinical-stage regenerative medicine company pioneering a new generation of hair loss treatments, today announced positive results demonstrating that its novel small molecule therapy PP405 reactivates dormant hair follicle stem cells and induces hair growth. Presented translational clinical data and phase 1 clinical data. The data were presented at the latest oral session. American Academy of Dermatology (AAD) 2024 Annual Meeting san diego,title Inhibiting pyruvate oxidation activates human hair follicle stem cells in vitro.

“Translational data from ex vivo studies on human facelift skin were further validated in a Phase 1 first-in-human clinical trial, demonstrating that PP405 effectively reactivates dormant hair follicle stem cells. This has been proven,” he said. daniel gillPh.D., CEO perage pharmaceutical. “This therapy represents an exciting new option for not only treating but reversing hair loss. We look forward to advancing PP405 into Phase 2 clinical trials this year.”

PP405 is a potent local mitochondrial pyruvate carrier (MPC) inhibitor that acts on cellular metabolic pathways to upregulate lactate dehydrogenase (LDH). Lactate dehydrogenase (LDH) is a enzyme to which stem cells are particularly sensitive, leading to activation and hair growth.

Data presented at AAD showed that a single topical application of 0.006% and 0.06% PP405 increased LDH activity in hair follicle stem cells within 24 hours in human facelifted skin. LDH activity coincided with a significant increase in Ki67 signal in the hair bulge, indicating a proliferative response of hair follicle stem cells. This finding demonstrated mechanistic evidence in human explanted skin, consistent with results in animal models.

This data influenced Pelage’s Phase 1 clinical trial, which concluded: January 2024This demonstrated that PP405 was safe and well-tolerated, and the targeted pharmacokinetic profile was achieved. Furthermore, a phase 1 study demonstrated evidence of mechanism and target involvement in patients with androgenetic alopecia. After just 7 days of his 0.05% PP405 topical treatment, he saw a statistically significant increase in Ki67 signal compared to baseline. Evidence of newly emerged hair germs, characteristic of the transition from telogen to anagen, was also observed. The topical molecule also received positive formulation reviews from patients.

“We are very excited about this data. PP405 offers a game-changing opportunity for hair loss treatment by directly targeting the hair follicle stem cells of origin through distinct mechanistic pathways. ” he said. Ching Yu Christina WenMD, CMO perage pharmaceutical. “The Phase 1b study of PP405 demonstrated a strong safety profile, confirmed daily topical administration with undetectable drug concentrations in the blood, and provided mechanistic evidence of statistically significant activation of hair follicle stem cells. We can also see the structural architecture of PP405 in a biopsied hair follicle transitioning through the hair cycle from telogen to anagen as stem cells become activated. ”

Pelage plans to begin a multicenter Phase 2a trial of PP405 in mid-2024, recruiting both men and women with androgenetic alopecia. PP405 may also have applications in other forms of hair loss, such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.

about perage pharmaceutical

perage pharmaceutical is a clinical-stage regenerative medicine company developing new treatments for hair loss, including androgenetic alopecia and chemotherapy-induced alopecia. Focused on molecular biology and stem cell biology, Pelage advances a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to grow hair naturally. doing. Its lead program, his PP405, is currently in clinical trials. Through rigorous scientific evidence, topical formulations, and a novel mechanism of action, Pelage is pioneering a first-in-class hair growth solution for people of all hair types experiencing hair loss.

About PP405

PP405 is a novel non-invasive topical small molecule designed to reactivate dormant hair follicle stem cells and restart hair growth. This treatment focuses on addressing the metabolic processes that regulate the activation and inactivation phases of hair follicle stem cells through a regenerative medicine approach. Early results from a Phase 1 study indicate that PP405 was well tolerated and demonstrated statistically significant activation of hair follicle stem cells. In 2018, perage pharmaceutical Licensed intellectual property to PP405 and related topical small molecules. UCLA Technology Development Group.

View original content to download multimedia: https://www.prnewswire.com/news-releases/pelage-presents-late-breaking-data-at-aad-2024-meeting-demonstrated- pp405-activates-human-hair-follicle -stem cells-ex-vivo-and-in-phase-1-clinical-study-302084610.html

sauce perage pharmaceutical